PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · World J Nucl Med 2021; 20(03): 222-227
DOI: 10.4103/wjnm.WJNM_47_20
Original Article

Determination of administered activities for the treatment of Graves' disease with iodine-131: Proposition of a simplified dosimetric procedure

Authors

  • Idrissa Adamou Soli

    1   Department of Nuclear Medicine Radio-Isotopes Institute, Niamey, Niger

  • Djibrillou Moussa Issoufou

    1   Department of Nuclear Medicine Radio-Isotopes Institute, Niamey, Niger
    2   Faculty of Medicine, Abdou Moumouni University, Niamey, Niger

  • Skander Rahabi

    3   Department of Nuclear Medicine, CHU de Bab El Oued, Algiers, Algeria

  • Ada Ali

    1   Department of Nuclear Medicine Radio-Isotopes Institute, Niamey, Niger
    2   Faculty of Medicine, Abdou Moumouni University, Niamey, Niger

  • Eric Adehossi

    2   Faculty of Medicine, Abdou Moumouni University, Niamey, Niger

  • Salah Eddine Bouyoucef

    3   Department of Nuclear Medicine, CHU de Bab El Oued, Algiers, Algeria
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints
Preview

Abstract

This prospective study included 35 patients suffering from Graves' disease (GD) clinically and biologically confirmed by endocrinologists, sent to the nuclear medicine department of CHU de Bab El Oued, Algiers for iodine-131 therapy. CHU de Bab El Oued is a tertiary hospital located in the center of the capital Algiers. The aim of this study is to propose a simplified dosimetric procedure which will initiate iodine-131 therapy of GD in particular and hyperthyroidism in general in Niger. The determination of the maximum uptake was performed with a Biodex external probe at 2 h, 4 h, and 24 h after the administration of 3 MBq of liquid iodine-131. The iodine-131 activities were determined using the Marinelli formula with a predefined effective half-life (Te) of 5 days and subsequently extrapolated half-life with kaleidagraph software. The statistical analysis was performed using an excel sheet and analyzed using the software package Statistica 10 (stat Soft, Tulsa, USA). the male:female gender ratio was1:4.5 and the mean age was 42.56 years (±7.14). The body mass index was within normal range with a value of 25.25 kg2 (±0.42) and the mean average thyroid mass was equal to 24.05 (±10.53) g. The mean uptake value at 24 h was 43.24% (±17.68%) meanwhile the maximum uptake value was 46.28 (±21.13%). The estimated effective half-life (Te) was 5.44 days (±1.96) days which were different from the predefined Te of 5 days. The mean activity determined with fixed Te and 24 h uptake was 244.45 (±109.2) MBq and the mean activity calculated with both extrapolated Te and maximum uptake was 452.22 (±381.9) MBq. Empirical determination of activity in the treatment of GD gives higher activities (1.5 times) to patients than dosimetric methods based on the determination of extrapolated effective half-life.

Keywords

Dosimetry - empiric activities - extrapolated effective half-life - optimization - planning - predefined effective half-life - uptake

Acknowledgments

The authors would like to thank the International Atomic Energy Agency, all the personal of the Service de Médecine Nucléaire du CHU de Bab El-Oued, Algiers-Algeria for their help.


Financial support and sponsorship

Nil.




Publikationsverlauf

Eingereicht: 02. Mai 2020

Angenommen: 17. Dezember 2020

Artikel online veröffentlicht:
24. März 2022

© 2021. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, et al. The SNM practice Guideline for therapy of thyroid disease with 131I, 3.0. J Nucl Med 2012;53:1633-51.
  • 2 GAMBO CM. Troubles métaboliques et endocrinopathie associées à la maladie de Basedow, thèse Med N1876, Niger, 2011 pp1-76.
  • 3 International Commission on Radiation Units and Measurements Report n. 67, Absorbed-dose Specification in Nuclear Medicine. Ashford, England: Nuclear Technology Publishing; 2002.
  • 4 European Union. Council Directive 97/43/EURATOM on health protection of individuals against the dangers of ionising radiation in relation to medical exposure. Luxembourg: Council of the European Union; 1997. Available from: http://ec.europa.eu/energy/nuclear/radioprotection/doc/legislation/9743_en.pdf. [Last Accessed on 2020 Jul 06].
  • 5 Janzen T, Guissani A, Canzi C, Gerundini P, Oeh U, Hoeschen C, et al. Investigation of biokinetics of radioiodine with a population kinetics approach. Radiat Prot Dosimetry 2010;39:232-5.
  • 6 Matheoud R, Canzi C, Reschini E, Zito F, Voltini F, Gerundini P, et al. Tissue-specific dosimetry for radioiodine therapy of the autonomous thyroid nodule. Am Assoc Phys Med 2003;30:791-8.
  • 7 Canzi C, zito F, Voltini F, Reschini E, Gerundini P, et al. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients. Am Assoc Phys Med 2006;33:2860-7.
  • 8 Berg GE, Michanek AM, Holmberg EC, Fink M. Iodine-131 treatment of hyperthyroidism: Significance of effective half-life measurements. J Nucl Med 1996;37:228-32.
  • 9 Willegaignon J, Sapienza MT, Filho GB, Tranino AC, Buchpigual CA. Determining thyroid 131I effective half-life for the treatment planning of Graves' disease. Am Assoc Phys Med 2013;40.
  • 10 Brent GA. Clinical practice, Graves' disease. N Engl J Med 2008;358:2594-605.
  • 11 Zhang R, Zhang G, Wang R, Tan J, He Y, Meng Z. Preduction of thyroidal 131 Iodine effective half-life in patient with Graves' disease. Oncotarget 2017;8:80934-40.
  • 12 Steve L Hyer, Brenda Pratt, Matthew Gray, Sarah Chittenden, Yong Du, Clive L Harmer, Glenn D Flux, Dosimetry-based treatment for Graves' disease, Nuclear Medicine Communications 2018, Vol 39,N°6:486-492.
  • 13 Clerc J, Izembart M, Dagousset F, Jaïs JP, Heshmati HM, Chevalier A, et al. Influence of dose selection on absorbed dose profiles in radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole. J Nucl Med 1993;34:387-93.